aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
December 21 2017 - 8:00AM
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of immuno-modulatory protein
therapeutics to treat patients suffering from rare, severe,
immune-mediated diseases, as well as various cancers, will present
data from the company’s ORCA program highlighting the potential
importance of Resokine in immuno-oncology at the ASCO-SITC clinical
immuno-oncology symposium. The ORCA program seeks to develop
antibodies to extracellular histidyl-tRNA synthetase (HARS), known
as the Resokine pathway, as a potential new therapy in
immuno-oncology. aTyr has selected and is developing a panel of
antibodies in IND-enabling activities with patient trials to
commence as early as 2019.
Poster Session: Thursday, January 25, 2018 from
11:30 am – 1:00 pm (PT) and 5:30 pm – 6:30 pm (PT)
- Abstract Title: Identification of Novel
Liquid Biopsy Biomarker for Monitoring the Immune Set Point in Both
Solid Tumor and Hematological Malignancy Patients
- Author: David King, Ph.D., aTyr
Pharma, Inc., San Diego, CA
- Location: San Francisco Marriott Marquis, San
Francisco, CA
About ORCA
ORCA is a preclinical research program that targets a novel,
proprietary immuno-oncology pathway using antibodies to change
levels of extracellular histidyl-tRNA synthetase (HARS), known as
the Resokine pathway, in tumor settings. aTyr believes tumors,
across multiple tumor types, utilize the Resokine pathway to evade
immune system responses. aTyr has evaluated the therapeutic
potential of targeting this novel pathway in multiple in-vitro and
in-vivo tumor models, in comparison to and in combination with
incumbent check-point modulators. Based on the tumor model
data, the company believes that targeting this pathway may reduce
or, in some cases, reverse tumor growth either as a monotherapy or
in combination therapy.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of
innovative medicines for patients using its knowledge of
Physiocrine biology, a newly discovered set of immunological and
physiological pathways. To date, aTyr has generated three
innovative and unique development programs based on its knowledge
of extracellular histidyl-tRNA synthetase (HARS), known as the
Resokine pathway. aTyr is developing potential therapeutic
applications based on the Resokine pathway to treat patients
suffering from rare, severe, immune-mediated diseases, as well as
various cancers. aTyr’s two clinical-stage programs, ATYR1940
(Resolaris) and ATYR1923 (iMod.Fc), are agonists of the Resokine
pathway designed to temper immune engagement in diseases
characterized by excessive immune cell involvement in muscle and
lung. aTyr’s third program, ORCA, represents a pre-clinical
research program that targets a novel, proprietary immuno-oncology
pathway using antibodies to enhance the immune response in tumor
settings. aTyr has built an intellectual property estate, to
protect its pipeline, comprising over 220 issued patents or allowed
patent applications that are owned or exclusively licensed,
including over 300 potential Physiocrine-based protein
compositions. For more information, please visit
http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act.
Forward-looking statements are usually identified by the use of
words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,”
and variations of such words or similar expressions. We intend
these forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including statements
regarding the potential and potential therapeutic benefits of
ATYR1940 (Resolaris), ATYR1923 (iMod.Fc), or potential product
candidates from our ORCA program, the ability of the Company to
successfully advance our pipeline or product candidates, undertake
certain development activities (such as clinical trial enrollment
and the conduct of clinical trials) and accomplish certain
development goals and the timing of such activities and development
goals, the timing of our clinical trials, our ability to receive
regulatory approvals for, and commercialize, our product candidates
and of reporting results from our clinical trials, and the scope
and strength of our intellectual property portfolio, reflect
our current views about our plans, intentions, expectations,
strategies and prospects, which are based on the information
currently available to us and on assumptions we have made.
Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control including, without limitation, risks associated
with the discovery, development and regulation of our
Physiocrine-based product candidates, the risk that we may cease or
delay preclinical or clinical development activities for any of its
existing or future product candidates for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), and the risk that we may not be able to raise the
additional funding required for our business and product
development plans, as well as those set forth in our most recent
Annual Report on Form 10-K for the year ended December 31, 2016 and
in our other SEC filings. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact: |
Mark Johnson |
Sr. Director, Investor
Relations |
mjohnson@atyrpharma.com |
858-223-1163 |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024